Second phase I/IIa trial of AVX 001 for the treatment of psoriasis
Latest Information Update: 23 Jan 2020
Price :
$35 *
At a glance
- Drugs AVX 001 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Avexxin; Coegin Pharma
- 02 Jul 2015 Results published in the Media Release.
- 02 Jul 2015 According to Avexxin media release, status changed from active not recruiting to completed.
- 26 Nov 2012 New trial record